Fentora

Fentora is a brand name of fentanyl, approved by the FDA in the following formulation(s):

FENTORA (fentanyl citrate - tablet; buccal)

• 
  Manufacturer: CEPHALON
  
  Approval date: September 25, 2006
  
  Strength(s): EQ 0.1MG BASE ^[AB], EQ 0.2MG BASE ^[AB], EQ 0.4MG BASE ^[RLD][AB], EQ 0.6MG BASE ^[AB], EQ 0.8MG BASE ^[AB]

Has a generic version of Fentora been approved?

A generic version of Fentora has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fentora and have been approved by the FDA:

fentanyl citrate tablet; buccal

• 
  Manufacturer: WATSON LABS
  
  Approval date: January 7, 2011
  
  Strength(s): EQ 0.1MG BASE ^[AB], EQ 0.2MG BASE ^[AB], EQ 0.4MG BASE ^[AB], EQ 0.6MG BASE ^[AB], EQ 0.8MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fentora. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Sublingual buccal effervescent
  Patent 6,200,604
  Issued: March 13, 2001
  Inventor(s): Pather; Sathasivan Indiran & Khankari; Rajendra K. & Eichman; Jonathan D. & Robinson; Joseph R. & Hontz; John
  Assignee(s): Cima Labs Inc.
  A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
  
  Patent expiration dates:
  
  
  • March 26, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
  
  



• 
  Sublingual buccal effervescent
  Patent 6,974,590
  Issued: December 13, 2005
  Inventor(s): Pather; Sathasivan Indiran & Khankari; Rajendra K. & Eichman; Jonathan D. & Robinson; Joseph R. & Hontz; John
  Assignee(s): Cima Labs Inc.
  A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
  
  Patent expiration dates:
  
  
  • March 26, 2019
    
    ✓ 
    Patent use: MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
  
  



• 
  Generally linear effervescent oral fentanyl dosage form and methods of administering
  Patent 7,862,832
  Issued: January 4, 2011
  Inventor(s): Moe; Derek & Agarwal; Vikas & Habib; Walid
  Assignee(s): Cima Labs, Inc.
  Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
  
  Patent expiration dates:
  
  
  • June 15, 2028
    
    ✓ 
    Drug product
  
  



• 
  Effervescent oral opiate dosage forms and methods of administering opiates
  Patent 7,862,833
  Issued: January 4, 2011
  Inventor(s): Moe; Derek
  Assignee(s): Cima Labs, Inc.
  Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
  
  Patent expiration dates:
  
  
  • June 15, 2028
    
    ✓ 
    Drug product
  
  



• 
  Generally linear effervescent oral fentanyl dosage form and methods of administering
  Patent 8,092,832
  Issued: January 10, 2012
  Inventor(s): Moe; Derek & Agarwal; Vikas & Habib; Walib
  Assignee(s): Cephalon, Inc.
  Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
  
  Patent expiration dates:
  
  
  • December 30, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Fentora Consumer Information (Drugs.com)
• Fentora Consumer Information (Wolters Kluwer)
• Fentora buccal Consumer Information (Cerner Multum)
• Fentora Advanced Consumer Information (Micromedex)
• Fentanyl Consumer Information (Drugs.com)
• Fentanyl Consumer Information (Wolters Kluwer)
• Fentanyl Lozenge Consumer Information (Wolters Kluwer)
• Fentanyl Patch Consumer Information (Wolters Kluwer)
• Fentanyl Soluble Film Consumer Information (Wolters Kluwer)
• Fentanyl Spray Consumer Information (Wolters Kluwer)
• Fentanyl Tablet Consumer Information (Wolters Kluwer)
• Fentanyl buccal Consumer Information (Cerner Multum)
• Fentanyl citrate oral transmucosal Consumer Information (Cerner Multum)
• Fentanyl nasal Consumer Information (Cerner Multum)
• Fentanyl sublingual Consumer Information (Cerner Multum)
• Fentanyl transdermal device Consumer Information (Cerner Multum)
• Fentanyl transdermal skin patch Consumer Information (Cerner Multum)
• Fentanyl Buccal mucosa, Oromucosal Advanced Consumer Information (Micromedex)
• Fentanyl Nasal Advanced Consumer Information (Micromedex)
• Fentanyl Transdermal Advanced Consumer Information (Micromedex)
• Fentanyl Citrate AHFS DI Monographs (ASHP)